Magnyl "DAK" 100 mg enterotabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

magnyl "dak" 100 mg enterotabletter

orifarm healthcare a/s - acetylsalicylsyre - enterotabletter - 100 mg

Magnyl "DAK" 500 mg tabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

magnyl "dak" 500 mg tabletter

orifarm healthcare a/s - acetylsalicylsyre - tabletter - 500 mg

Magnyl Svage "DAK" 150 mg filmovertrukne tabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

magnyl svage "dak" 150 mg filmovertrukne tabletter

orifarm healthcare a/s - acetylsalicylsyre - filmovertrukne tabletter - 150 mg

Quetiapin "Actavis" 100 mg filmovertrukne tabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

quetiapin "actavis" 100 mg filmovertrukne tabletter

actavis group ptc ehf. - quetiapin fumarat - filmovertrukne tabletter - 100 mg

Quetiapin "Actavis" 200 mg filmovertrukne tabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

quetiapin "actavis" 200 mg filmovertrukne tabletter

actavis group ptc ehf. - quetiapin fumarat - filmovertrukne tabletter - 200 mg

Quetiapin "Actavis" 25 mg filmovertrukne tabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

quetiapin "actavis" 25 mg filmovertrukne tabletter

actavis group ptc ehf. - quetiapin fumarat - filmovertrukne tabletter - 25 mg

Quetiapin "Actavis" 300 mg filmovertrukne tabletter Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

quetiapin "actavis" 300 mg filmovertrukne tabletter

actavis group ptc ehf. - quetiapin fumarat - filmovertrukne tabletter - 300 mg

Ogluo Európska únia - dánčina - EMA (European Medicines Agency)

ogluo

tetris pharma b.v - glucagon - diabetes mellitus - pancreas hormoner, hormoner glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Pombiliti Európska únia - dánčina - EMA (European Medicines Agency)

pombiliti

amicus therapeutics europe limited - cipaglucosidase alfa - glycogen opbevaring sygdom type ii - andre alimentary tract and metabolism produkter, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Opfolda Európska únia - dánčina - EMA (European Medicines Agency)

opfolda

amicus therapeutics europe limited - miglustat - glycogen opbevaring sygdom type ii - andre fordøjelseskanaler og stofskifteprodukter - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).